12/01/2021 | Spotlight
ACHEMA Inspire: Digitalisation could be an acceleration factor. How digitalised is the pharma industry right now?
ACHEMA Inspire: Siemens talks about an end-to-end Digital Enterprise Solution – what is your approach as far as the pharma industry is concerned?
ACHEMA Inspire: What are the benefits of a digital twin implementation?
In other words, twins of the product, productions, and performance will be linked. These offer high added value in biological processes, or where elements like physical models have to be better understood, as in the vaccination process. This would improve monitoring and control over all processes. The principle of “co-simulation” is key: Twins of individual part-processes are created first – from cell culture fermentation to purification, the specific formular, and the filling process, all of which will be combined at a later stage.
ACHEMA Inspire: Which of your software solutions realise a digital twin?
ACHEMA Inspire: In pharma, industrial software solutions will be the future. Could you elaborate the role you thin it will play?
And we are also developing specific Pharma Apps that leverage the data that is collected throughout the process to further enable batch release by exception and in real time. For the MRNA production in BioNTech there are over 50,000 different manufacturing steps in a batch that need to be recorded and reviewed. Digital solutions not only help us to reduce the review time, but also pick up potential errors that avoid reword and waste.
With our newsletter you will receive current information on ACHEMA on a regular basis. You are guaranteed not to miss any important dates.
60486 Frankfurt am Main
Tel.: +49 69 7564-100